-transparent.png){kind=logo}
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus. 2005
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
Department of Basic Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. Zhijian_lu@merck.com
Efforts directed to identifying potent HIV protease inhibitors (PI) have yielded a class of compounds that are not only very active against wild-type (NL4-3) HIV virus but also very potent against a panel of PI-resistant viral isolates. Chemistry and biology are described.
Related Publications
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
October 2007,
Bioorganic & medicinal chemistry letters,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
August 1996,
Journal of medicinal chemistry,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
June 2011,
Bioorganic & medicinal chemistry letters,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
April 1995,
Proceedings of the National Academy of Sciences of the United States of America,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
January 2012,
Bioorganic & medicinal chemistry letters,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
September 1994,
Bioorganic & medicinal chemistry,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
July 2008,
Expert opinion on drug discovery,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
February 2008,
Bioorganic & medicinal chemistry letters,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
August 2007,
Journal of medicinal chemistry,
Zhijian Lu, and
Joann Bohn, and
Tom Rano, and
Carrie A Rutkowski, and
Amy L Simcoe, and
David B Olsen, and
William A Schleif, and
Anthony Carella, and
Lori Gabryelski, and
Lixia Jin, and
Jiunn H Lin, and
Emilio Emini, and
Kevin Chapman, and
James R Tata
January 2004,
Journal of medicinal chemistry,
